Adjuvant therapy for colon cancer: genes, genes... and the patient in the center
Rodriguez J (1), Vicent S (2), Chopitea A (1), Ponz-Sarvise M (3).
(1) Medical Oncology, Clinica Universidad de Navarra, University of Navarra.
(2) Program of Solid Tumors, Center for Applied Medical Research (CIMA), University of Navarra.
(3) Medical Oncology, Clinica Universidad de Navarra/Center for Applied Medical Research (CIMA), University of Navarra email@example.com.
Although molecular subtype-based stratification and genomic signatures of increasing complexity are becoming a new strategy to guide therapeutic decisions in stage II/III colon cancer, several prognostic factors that can be easily obtained from FFPE specimens should be considered in order to create combined models that better define individual patients needs.
CITATION Clin Cancer Res. 2018 Apr 20. pii: clincanres.0818.2018. doi: 10.1158/1078-0432.CCR-18-0818